Genetic testing for fertility-sparing endometrial cancer treatment
Part of Cancer, Women’s health & pregnancy clinical trials.
This study looks at how genetic features of early-stage endometrial cancer affect the success of fertility-sparing treatments. It aims to help women under 45 who want to preserve their fertility understand their treatment options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 45 years old.
- You have been diagnosed with early-stage endometrial cancer (type 1, grade 1 or 2, without spreading into the muscle layer).
- You want to preserve fertility.
- Your tumor can be genetically tested (requires a good-quality biopsy).
- You have had an MRI or vaginal ultrasound showing the cancer has not spread.
- You do not have other cancers or medical reasons that prevent hormonal therapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a tailored approach to preserve fertility in women with early-stage endometrial cancer, using medications like hormones and immunotherapy based on the tumor's molecular subtype. It aims to avoid hysterectomy and keep the uterus intact.
This trial looks at a fertility-preserving treatment plan for people with early-stage endometrial cancer who want to keep the ability to have children. It may help you avoid surgery that removes fertility, if you meet the trial’s safety and eligibility rules.
This study looks at how ultrasound and tissue samples (histology) can better guide fertility-sparing treatment for early uterine cancer or precancer. It aims to improve how doctors decide on surgery or hormone therapy to preserve fertility.
This study looks at combining genetic testing with surgical exams to better understand endometrial cancer. It may help doctors see which treatments could work best for you.
This study tests a way to treat early-stage endometrial cancer without removing the uterus, so you can still have a chance to carry a pregnancy. It’s for women under 45 with a grade 2 tumor that hasn’t grown into the womb muscle.
This study tests two less invasive methods—sampling cells from the lining of the uterus (endometrial cytology) and checking DNA changes in the cervix—to see if they can help detect endometrial cancer or atypical hyperplasia, and to monitor response in people who are preserving their fertility. It aims to find a gentler alternative to traditional biopsy.
Hear when a new Uterine Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.